Loading...

Jcancom's Recent CancerCompass Activity

  • Jcancom has replied to a post on the message board

    critic, I have reviewed the original clinical study on vitamin C from the 1970s (Journal of Chemico-Biological Interactions 9 (1974) 285-315). They completely nailed it way back then. Hard to imagine that they have continued to argue about it for all of these decades; there's nothing to argue about the debate was over 50 years ago for those who read the article. [I recently went back to read the Warburg articles in ...

    November 18 at 1:01 AM view post
    • Jcancom has replied to a post on the message board

      Have the doctors suggested Isolated limb perfusion ?

      November 15 at 11:20 PM view post
      • Jcancom has replied to a post on the message board

        There has been some very very big news in melanoma over the last few days. NKTR214 reported very strong results in melanoma. http://www.nektar.com/application/files/8115/1042/7902/SITC2017_-Oral_Session_207_-_PIVOT-02_-_Adi_Diab-preso.pdf http://www.nektar.com/ Another company Calithera also presented strong results in melanoma. As shown in the pdf below the 3 or so responses happened quickly and could be predict...

        November 15 at 4:45 AM view post
        • Jcancom has replied to a post on the message board

          Wow!!!!! This is a massive day for humanity! It is like the first day you don't have to feel bad about being alive. Just massive massive results from Nektar. NKTR-214. Mel, RCC, NSCLC, (expansion into BL, TNBC). It looks going through the immune system with PD-1 and CD122 hits a bingo. Love to see what the next step is to amp this up! Might some alpha-c-galactosylceramide ramp up those NKs? Big big win for pharma ...

          November 13 at 11:33 PM view post
          • Jcancom has replied to a post on the message board

            critic, this is such an exciting time! From what I can see metabolic medicine truly is stepping ahead. I am now waiting for the next part of the MSCT protocol to fall into place to take this up a step. For example, a ketone ester product is entering the market this week. We have waited 20 years for this. Being able to drink the ketone ester and have a near immediate ketone pop to 5 mM could be quite useful in cancer...

            November 13 at 12:32 AM view post
            • Jcancom has replied to a post on the message board

              The survival chart shown at 5:18 of below url is quite startling. The Stage IV lung cancer patients under MSCT survived over 43 months for the more typically treated chemo comparison groups survival was between 6 and 11 months. We might have to wait a bit for a fuller interpretation of these results to emerge, though at first glance they look extremely good. http://chemothermia.com/results-of-metabolically-supporte...

              November 12 at 9:40 PM view post
              • Jcancom has replied to a post on the message board

                Perillyl alcohol (POH) came to the attention of the thread a few months ago when a report talked of conjugating POH and 3-BP. Many of us really did not know what to make of it. The article mentioned gaining cell access without needing MCT-1. That would be extremely helpful. MCT-1 is the only obstacle preventing very large responses, by essentially all cancer patients to 3-BP.   Here's the recent 3-BP report. Art...

                November 11 at 6:24 PM view post
                • Jcancom has replied to a post on the message board

                  3-Bromopyruvate is entering into the net's deep consciousness. 3-BP and metabolics are everywhere. Even in journal articles that are not pulled up in a search often will mention it.  The amping up of 3-BP is also well underway. The second generation 3-BP chemicals look very powerful; big question is whether they would be safe. The url provides an okish input with the idea of deuterating 3-BP. With DDW, deuteri...

                  November 10 at 2:45 AM view post
                  • Jcancom has replied to a post on the message board

                    I have been wondering for some time how a more comprehensive treatment protocol might be created. If we had a metabolic scaffold protocol that had been clinically established then we could top it up with others as needed.  It appears that such a protocol is emerging. Those on the thread might already be familiar with MSCT (Metabolically Supported Chemotherapy) which has been developing over the last few years....

                    November 07 at 11:17 PM view post
                    • Jcancom has replied to a post on the message board

                      Always on the look out for an amplified version of 3-BP. This one is from South Korea and it appears to me to top mito-3BP which we have discussed on thread. This latest one adds in TPP as the tug boat to move 3BP to the mitochondria, can also use the photothermal route and to top it off seems to be pH sensitive. This would push it above mito-3BP. The problem as with mit0-3BP: no in vivo. We are still not sure of th...

                      November 04 at 3:26 AM view post
                      Loading...
                      Load more activity
                      Loading more activity

                      About Jcancom

                      Jcancom has not shared any information about themselves. Send them a message to tell them you'd like to find out more about them or add them as a friend.

                      We care about your feedback. Let us know how we can improve your CancerCompass experience.